C-QAKXAltay Therapeutics
transcription factor inhibition, small molecules, allosteric sites
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-QAKX
C-QAKXC-QAKXtranscription factor inhibition, small molecules, allosteric sites
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Dr. Ali Ozes, Founder and CEO of Altay Therapeutics.
Innovating Therapeutics for Unmet Medical Need About Us Science Pipeline Team News CONTACT US About Us Science Pipeline Team News CONTACT US Unlocking Transcription Factors to Address Unmet Medical Need Developing small molecules with potential across multiple serious diseases about us Advancing Oral Transcription Factor Therapies for Patients with Limited Options At Altay Therapeutics, we're unlocking the therapeutic potential of transcription factor inhibition to address serious, underserved diseases. Our pipeline includes the first oral small molecule inhibitor of DUX4 for facioscapulo … Presentations JUN 2025 Altay is selected as a Finalist for the $10M FSHD Bonus Prize alongside the $101M XPrize Healthspan competition We're honored to have been selected as a Finalist for the $10M FSHD Bonus Prize alongside the $101M XPrize Healthspan competition. Read about it here. Dec 2023 Altay is awarded a Golden Ticket award by Astellas Therapeutics! We're honored to have been selected as a Golden Ticket recipient by Astellas Therapeutics! Read about it here